Latham & Watkins Advises on GSK’s US$2.2 Billion Acquisition of RAPT Therapeutics

GSK plc (LSE/NYSE: GSK) announced that it has entered a definitive agreement to acquire RAPT Therapeutics (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases. The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in phase IIb clinical development for prophylactic protection against food allergens. Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders US$58.00 per share at closing for an estimated aggregate equity value of US$2.2 billion. The transaction is expected to close in the first quarter of 2026.

Latham & Watkins LLP represents J.P. Morgan Securities LLC as financial advisor to RAPT Therapeutics in the transaction with a corporate team led by Orange County partners Charles Ruck and Brian Umanoff, with associate Tiana Baghdikian.